Recent evidence indicates that cyclophosphamide exposure increases the risk of hematologic malignancies in patients with rheumatoid arthritis. In a large administrative database cohort of patients ...

A study by Mellqvist et al. has assessed the efficacy and safety of combined bolus-dose cyclophosphamide and pulse-dose dexamethasone (Cy-Dex) as initial treatment for patients with myeloma.

Other effective therapies targeting the fibrotic mechanisms have not been developed despite the increased understanding of the key pathogenic pathways. The two pivotal studies of cyclophosphamide ...